Anthony Quinn

Director at Generation Bio

Anthony Quinn is president and chief executive officer at Aeglea BioTherapeutics. Previously, Dr. Quinn served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma Corp., until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, Anthony served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. Anthony received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London.

Roles

  • Director

    Current role

Social

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.